|
1
|
Pieper K, Grimbacher B and Eibel H: B-cell
biology and development. J Allergy Clin Immunol. 131:959–971. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hardy RR, Kincade PW and Dorshkind K: The
protean nature of cells in the B lymphocyte lineage. Immunity.
26:703–714. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jensen CT, Strid T and Sigvardsson M:
Exploring the multifaceted nature of the common lymphoid progenitor
compartment. Curr Opin Immunol. 39:121–126. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Suan D, Sundling C and Brink R: Plasma
cell and memory B cell differentiation from the germinal center.
Curr Opin Immunol. 45:97–102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kaliman P: Epigenetics and meditation.
Curr Opin Psychol. 28:76–80. 2019. View Article : Google Scholar
|
|
6
|
Silkenstedt E, Salles G, Campo E and
Dreyling M: B-cell non-Hodgkin lymphomas. Lancet. 403:1791–1807.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mu S, Wang W, Liu Q, Ke N, Li H, Sun F,
Zhang J and Zhu Z: Autoimmune disease: A view of epigenetics and
therapeutic targeting. Front Immunol. 15:14827282024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ghafouri-Fard S, Khoshbakht T, Hussen BM,
Taheri M and Jamali E: The emerging role non-coding RNAs in B
cell-related disorders. Cancer Cell Int. 22:912022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sermer D, Pasqualucci L, Wendel HG,
Melnick A and Younes A: Emerging epigenetic-modulating therapies in
lymphoma. Nat Rev Clin Oncol. 16:494–507. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gamarra N and Narlikar GJ: Collaboration
through chromatin: Motors of transcription and chromatin structure.
J Mol Biol. 433:1668762021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zheng H and Xie W: The role of 3D genome
organization in development and cell differentiation. Nat Rev Mol
Cell Biol. 20:535–550. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zaret KS: Pioneer Transcription factors
initiating gene network changes. Annu Rev Genet. 54:367–385. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Klemm SL, Shipony Z and Greenleaf WJ:
Chromatin accessibility and the regulatory epigenome. Nat Rev
Genet. 20:207–220. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chiarella AM, Lu D and Hathaway NA:
Epigenetic control of a local chromatin landscape. Int J Mol Sci.
21:9432020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nodelman IM and Bowman GD: Biophysics of
chromatin remodeling. Annu Rev Biophys. 50:73–93. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tan T, Shi P, Abbas MN, Wang Y, Xu J, Chen
Y and Cui H: Epigenetic modification regulates tumor progression
and metastasis through EMT (review). Int J Oncol. 60:702022.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lorch Y and Kornberg RD:
Chromatin-remodeling for transcription. Q Rev Biophys. 50:e52017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tanny JC: Chromatin modification by the
RNA polymerase II elongation complex. Transcription. 5:e9880932014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Moore LD, Le T and Fan G: DNA methylation
and its basic function. Neuropsychopharmacology. 38:23–38. 2013.
View Article : Google Scholar
|
|
20
|
López-Moyado IF, Ko M, Hogan PG and Rao A:
TET enzymes in the immune system: From DNA demethylation to
immunotherapy, inflammation, and cancer. Annu Rev Immunol.
42:455–488. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gigek CO, Chen ES and Smith MA:
Methyl-CpG-binding protein (MBD) family: Epigenomic read-outs
functions and roles in tumorigenesis and psychiatric diseases. J
Cell Biochem. 117:29–38. 2016. View Article : Google Scholar
|
|
22
|
Kouzarides T: Chromatin modifications and
their function. Cell. 128:693–705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shvedunova M and Akhtar A: Modulation of
cellular processes by histone and non-histone protein acetylation.
Nat Rev Mol Cell Biol. 23:329–349. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sabari BR, Zhang D, Allis CD and Zhao Y:
Metabolic regulation of gene expression through histone acylations.
Nat Rev Mol Cell Biol. 18:90–101. 2017. View Article : Google Scholar :
|
|
25
|
Jambhekar A, Dhall A and Shi Y: Roles and
regulation of histone methylation in animal development. Nat Rev
Mol Cell Biol. 20:625–641. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mattiroli F and Penengo L: Histone
ubiquitination: An integrative signaling platform in genome
stability. Trends Genet. 37:566–581. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Oss-Ronen L, Sarusi T and Cohen I: Histone
mono-ubiquitination in transcriptional regulation and its mark on
life: Emerging roles in tissue development and disease. Cells.
11:24042022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lim PS, Li J, Holloway AF and Rao S:
Epigenetic regulation of inducible gene expression in the immune
system. Immunology. 139:285–293. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Su N, Yu X, Duan M and Shi N: Recent
advances in methylation modifications of microRNA. Genes Dis.
12:1012012023. View Article : Google Scholar
|
|
30
|
Saliminejad K, Khorram Khorshid HR,
Soleymani Fard S and Ghaffari SH: An overview of microRNAs:
Biology, functions, therapeutics, and analysis methods. J Cell
Physiol. 234:5451–5465. 2019. View Article : Google Scholar
|
|
31
|
Nguyen TA, Park J, Dang TL, Choi YG and
Kim VN: Microprocessor depends on hemin to recognize the apical
loop of primary microRNA. Nucleic Acids Res. 46:5726–5736. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wilson RC, Tambe A, Kidwell MA, Noland CL,
Schneider CP and Doudna JA: Dicer-TRBP complex formation ensures
accurate mammalian MicroRNA biogenesis. Mol Cell. 57:397–407. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fareh M, Yeom KH, Haagsma AC, Chauhan S,
Heo I and Joo C: TRBP ensures efficient Dicer processing of
precursor microRNA in RNA-crowded environments. Nat Commun.
7:136942016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bartel DP: Metazoan MicroRNAs. Cell.
173:20–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Abdelfattah AM, Park C and Choi MY: Update
on non-canonical microRNAs. Biomol Concepts. 5:275–287. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Coyle MC and King N: The evolutionary
foundations of transcriptional regulation in animals. Nat Rev
Genet. 26:812–827. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen LL and Kim VN: Small and long
non-coding RNAs: Past, present, and future. Cell. 187:6451–6485.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Winkle M, Kluiver JL, Diepstra A and van
den Berg A: Emerging roles for long noncoding RNAs in B-cell
development and malignancy. Crit Rev Oncol Hematol. 120:77–85.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mattick JS, Amaral PP, Carninci P,
Carpenter S, Chang HY, Chen LL, Chen R, Dean C, Dinger ME,
Fitzgerald KA, et al: Long non-coding RNAs: Definitions, functions,
challenges and recommendations. Nat Rev Mol Cell Biol. 24:430–447.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Statello L, Guo CJ, Chen LL and Huarte M:
Gene regulation by long non-coding RNAs and its biological
functions. Nat Rev Mol Cell Biol. 22:96–118. 2021. View Article : Google Scholar
|
|
42
|
Gail EH, Healy E, Flanigan SF, Jones N, Ng
XH, Uckelmann M, Levina V, Zhang Q and Davidovich C: Inseparable
RNA binding and chromatin modification activities of a
nucleosome-interacting surface in EZH2. Nat Genet. 56:1193–1202.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tan JY and Marques AC: The activity of
human enhancers is modulated by the splicing of their associated
lncRNAs. PLoS Comput Biol. 18:e10097222022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang Y, Liu H, Niu M, Wang Y, Xu R, Guo Y
and Zhang C: Roles of long noncoding RNAs in human inflammatory
diseases. Cell Death Discov. 10:2352024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Corfe SA and Paige CJ: The many roles of
IL-7 in B cell development; mediator of survival, proliferation and
differentiation. Semin Immunol. 24:198–208. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Egawa T, Kawabata K, Kawamoto H, Amada K,
Okamoto R, Fujii N, Kishimoto T, Katsura Y and Nagasawa T: The
earliest stages of B cell development require a chemokine stromal
cell-derived factor/pre-B cell growth-stimulating factor. Immunity.
15:323–334. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhiming W, Luman W, Tingting Q and Yiwei
C: Chemokines and receptors in intestinal B lymphocytes. J Leukoc
Biol. 103:807–819. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Maeda T, Merghoub T, Hobbs RM, Dong L,
Maeda M, Zakrzewski J, van den Brink MR, Zelent A, Shigematsu H,
Akashi K, et al: Regulation of B versus T lymphoid lineage fate
decision by the proto-oncogene LRF. Science. 316:860–866. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kosan C, Saba I, Godmann M, Herold S,
Herkert B, Eilers M and Möröy T: Transcription factor miz-1 is
required to regulate interleukin-7 receptor signaling at early
commitment stages of B cell differentiation. Immunity. 33:917–928.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bosticardo M, Pala F and Notarangelo LD:
RAG deficiencies: Recent advances in disease pathogenesis and novel
therapeutic approaches. Eur J Immunol. 51:1028–1038. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Rolink AG, Tschopp J, Schneider P and
Melchers F: BAFF is a survival and maturation factor for mouse B
cells. Eur J Immunol. 32:2004–2010. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
De Silva NS and Klein U: Dynamics of B
cells in germinal centres. Nat Rev Immunol. 15:137–148. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Stavnezer J, Guikema JE and Schrader CE:
Mechanism and regulation of class switch recombination. Annu Rev
Immunol. 26:261–292. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Nera KP, Kyläniemi MK and Lassila O:
Regulation of B cell to plasma cell transition within the
follicular B cell response. Scand J Immunol. 82:225–234. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Victora GD and Nussenzweig MC: Germinal
centers. Annu Rev Immunol. 30:429–457. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Shapiro-Shelef M, Lin KI,
McHeyzer-Williams LJ, Liao J, McHeyzer-Williams MG and Calame K:
Blimp-1 is required for the formation of immunoglobulin secreting
plasma cells and pre-plasma memory B cells. Immunity. 19:607–620.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Martin-Subero JI and Oakes CC: Charting
the dynamic epigenome during B-cell development. Semin Cancer Biol.
51:139–148. 2018. View Article : Google Scholar
|
|
58
|
Lai AY, Mav D, Shah R, Grimm SA, Phadke D,
Hatzi K, Melnick A, Geigerman C, Sobol SE, Jaye DL and Wade PA: DNA
methylation profiling in human B cells reveals immune regulatory
elements and epigenetic plasticity at Alu elements during B-cell
activation. Genome Res. 23:2030–2041. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Schuyler RP, Merkel A, Raineri E, Altucci
L, Vellenga E, Martens JHA, Pourfarzad F, Kuijpers TW, Burden F,
Farrow S, et al: Distinct trends of DNA methylation patterning in
the innate and adaptive immune systems. Cell Rep. 17:2101–2111.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Odegard VH, Kim ST, Anderson SM, Shlomchik
MJ and Schatz DG: Histone modifications associated with somatic
hypermutation. Immunity. 23:101–110. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Begum NA, Stanlie A, Nakata M, Akiyama H
and Honjo T: The histone chaperone Spt6 is required for
activation-induced cytidine deaminase target determination through
H3K4me3 regulation. J Biol Chem. 287:32415–32429. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Cyster JG and Allen CDC: B cell responses:
Cell interaction dynamics and decisions. Cell. 177:524–540. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Victora GD and Nussenzweig MC: Germinal
centers. Annu Rev Immunol. 40:413–442. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Fujimura S, Matsui T, Kuwahara K, Maeda K
and Sakaguchi N: Germinal center B-cell-associated DNA
hypomethylation at transcriptional regions of the AID gene. Mol
Immunol. 45:1712–1719. 2008. View Article : Google Scholar
|
|
65
|
Barwick BG, Scharer CD, Martinez RJ, Price
MJ, Wein AN, Haines RR, Bally APR, Kohlmeier JE and Boss JM: B cell
activation and plasma cell differentiation are inhibited by de novo
DNA methylation. Nat Commun. 9:19002018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Manoharan A, Du Roure C, Rolink AG and
Matthias P: De novo DNA Methyltransferases Dnmt3a and Dnmt3b
regulate the onset of Igκ light chain rearrangement during early
B-cell development. Eur J Immunol. 45:2343–2355. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Shaknovich R, Cerchietti L, Tsikitas L,
Kormaksson M, De S, Figueroa ME, Ballon G, Yang SN, Weinhold N,
Reimers M, et al: DNA methyltransferase 1 and DNA methylation
patterning contribute to germinal center B-cell differentiation.
Blood. 118:3559–3569. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Orlanski S, Labi V, Reizel Y, Spiro A,
Lichtenstein M, Levin-Klein R, Koralov SB, Skversky Y, Rajewsky K,
Cedar H and Bergman Y: Tissue-specific DNA demethylation is
required for proper B-cell differentiation and function. Proc Natl
Acad Sci USA. 113:5018–5023. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Millán-Zambrano G, Burton A, Bannister AJ
and Schneider R: Histone post-translational modifications-cause and
consequence of genome function. Nat Rev Genet. 23:563–580. 2022.
View Article : Google Scholar
|
|
70
|
Konuma T and Zhou MM: Distinct histone H3
lysine 27 modifications dictate different outcomes of gene
transcription. J Mol Biol. 436:1683762024. View Article : Google Scholar
|
|
71
|
Weake VM and Workman JL: Histone
ubiquitination: Triggering gene activity. Mol Cell. 29:653–663.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Chowdhury M, Forouhi O, Dayal S, McCloskey
N, Gould HJ, Felsenfeld G and Fear DJ: Analysis of intergenic
transcription and histone modification across the human
immunoglobulin heavy-chain locus. Proc Natl Acad Sci USA.
105:15872–15877. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Crouch EE, Li Z, Takizawa M,
Fichtner-Feigl S, Gourzi P, Montaño C, Feigenbaum L, Wilson P, Janz
S, Papavasiliou FN and Casellas R: Regulation of AID expression in
the immune response. J Exp Med. 204:1145–1156. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Liu Z, Mai A and Sun J: Lysine acetylation
regulates Bruton's tyrosine kinase in B cell activation. J Immunol.
184:244–254. 2010. View Article : Google Scholar
|
|
75
|
Iwama A, Oguro H, Negishi M, Kato Y and
Nakauchia H: Epigenetic regulation of hematopoietic stem cell
self-renewal by polycomb group genes. Int J Hematol. 81:294–300.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Gu Y, Jones AE, Yang W, Liu S, Dai Q, Liu
Y, Swindle CS, Zhou D, Zhang Z, Ryan TM, et al: The histone H2A
deubiquitinase Usp16 regulates hematopoiesis and hematopoietic stem
cell function. Proc Natl Acad Sci USA. 113:E51–E60. 2016.
View Article : Google Scholar :
|
|
77
|
Li C, Irrazabal T, So CC, Berru M, Du L,
Lam E, Ling AK, Gommerman JL, Pan-Hammarström Q and Martin A: The
H2B deubiquitinase Usp22 promotes antibody class switch
recombination by facilitating non-homologous end joining. Nat
Commun. 9:10062018. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
So CC, Ramachandran S and Martin A: E3
ubiquitin ligases RNF20 and RNF40 are required for double-stranded
break (DSB) repair: Evidence for monoubiquitination of histone H2B
lysine 120 as a novel axis of DSB signaling and repair. Mol Cell
Biol. 39:e00488–18. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Chen CZ, Li L, Lodish HF and Bartel DP:
MicroRNAs modulate hematopoietic lineage differentiation. Science.
303:83–86. 2004. View Article : Google Scholar
|
|
80
|
Ventura A, Young AG, Winslow MM, Lintault
L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone
JR, et al: Targeted deletion reveals essential and overlapping
functions of the miR-17 through 92 family of miRNA clusters. Cell.
132:875–886. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Rao DS, O'Connell RM, Chaudhuri AA,
Garcia-Flores Y, Geiger TL and Baltimore D: MicroRNA-34a perturbs B
lymphocyte development by repressing the forkhead box transcription
factor Foxp1. Immunity. 33:48–59. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Xiao C, Calado DP, Galler G, Thai TH,
Patterson HC, Wang J, Rajewsky N, Bender TP and Rajewsky K: MiR-150
controls B cell differentiation by targeting the transcription
factor c-Myb. Cell. 131:146–159. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Mehta A, Mann M, Zhao JL, Marinov GK,
Majumdar D, Garcia-Flores Y, Du X, Erikci E, Chowdhury K and
Baltimore D: The microRNA-212/132 cluster regulates B cell
development by targeting Sox4. J Exp Med. 212:1679–1692. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
King JK, Ung NM, Paing MH, Contreras JR,
Alberti MO, Fernando TR, Zhang K, Pellegrini M and Rao DS:
Regulation of marginal zone B-cell differentiation by
MicroRNA-146a. Front Immunol. 7:6702017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Thai TH, Calado DP, Casola S, Ansel KM,
Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela D, Kutok JL, et
al: Regulation of the germinal center response by microRNA-155.
Science. 316:604–608. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Vigorito E, Perks KL, Abreu-Goodger C,
Bunting S, Xiang Z, Kohlhaas S, Das PP, Miska EA, Rodriguez A,
Bradley A, et al: microRNA-155 regulates the generation of
immunoglobulin class-switched plasma cells. Immunity. 27:847–859.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Kramer NJ, Wang WL, Reyes EY, Kumar B,
Chen CC, Ramakrishna C, Cantin EM, Vonderfecht SL, Taganov KD, Chau
N and Boldin MP: Altered lymphopoiesis and immunodeficiency in
miR-142 null mice. Blood. 125:3720–3730. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Wigton EJ and Ansel KM: Noncoding RNAs in
B cell responses. RNA Biol. 18:633–639. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Brazão TF, Johnson JS, Müller J, Heger A,
Ponting CP and Tybulewicz VL: Long noncoding RNAs in B-cell
development and activation. Blood. 128:e10–e19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Tschumper RC, Hoelzinger DB, Walters DK,
Davila JI, Osborne CA and Jelinek DF: Stage-specific non-coding RNA
expression patterns during in vitro human B cell differentiation
into antibody secreting plasma cells. Noncoding RNA.
8:152022.PubMed/NCBI
|
|
91
|
Petri A, Dybkær K, Bøgsted M, Thrue CA,
Hagedorn PH, Schmitz A, Bødker JS, Johnsen HE and Kauppinen S: Long
noncoding RNA expression during human B-cell development. PLoS One.
10:e01382362015. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Mielczarek O, Rogers CH, Zhan Y, Matheson
LS, Stubbington MJT, Schoenfelder S, Bolland DJ, Javierre BM,
Wingett SW, Várnai C, et al: Intra- and interchromosomal contact
mapping reveals the Igh locus has extensive conformational
heterogeneity and interacts with B-lineage genes. Cell Rep.
42:1130742023. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Rothschild G, Zhang W, Lim J, Giri PK,
Laffleur B, Chen Y, Fang M, Chen Y, Nair L, Liu ZP, et al:
Noncoding RNA transcription alters chromosomal topology to promote
isotype-specific class switch recombination. Sci Immunol.
5:eaay58642020. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Luo M, Jeong M, Sun D, Park HJ, Rodriguez
BA, Xia Z, Yang L, Zhang X, Sheng K, Darlington GJ, et al: Long
non-coding RNAs control hematopoietic stem cell function. Cell Stem
Cell. 16:426–438. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Yu B, Qi Y, Li R, Shi Q, Satpathy AT and
Chang HY: B cell-specific XIST complex enforces X-inactivation and
restrains atypical B cells. Cell. 184:1790–1803.e17. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Kiriakidou M and Ching CL: Systemic lupus
erythematosus. Ann Intern Med. 172:ITC81–ITC96. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Dai X, Fan Y and Zhao X: Systemic lupus
erythematosus: Updated insights on the pathogenesis, diagnosis,
prevention and therapeutics. Signal Transduct Target Ther.
10:1022025. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Ulff-Møller CJ, Asmar F, Liu Y, Svendsen
AJ, Busato F, Grønbaek K, Tost J and Jacobsen S: Twin DNA
methylation profiling reveals flare-dependent interferon signature
and B cell promoter hypermethylation in systemic lupus
erythematosus. Arthritis Rheumatol. 70:878–890. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Absher DM, Li X, Waite LL, Gibson A,
Roberts K, Edberg J, Chatham WW and Kimberly RP: Genome-wide DNA
methylation analysis of systemic lupus erythematosus reveals
persistent hypomethylation of interferon genes and compositional
changes to CD4+ T-cell populations. PLoS Genet. 9:e10036782013.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Fali T, Le Dantec C, Thabet Y, Jousse S,
Hanrotel C, Youinou P, Brooks WH, Perl A and Renaudineau Y: DNA
methylation modulates HRES1/p28 expression in B cells from patients
with lupus. Autoimmunity. 47:265–271. 2014. View Article : Google Scholar :
|
|
101
|
Hui-Yuen J, Jiang K, Malkiel S, Eberhard
BA, Walters H, Diamond B and Jarvis J: B lymphocytes in
treatment-naive paediatric patients with lupus are epigenetically
distinct from healthy children. Lupus Sci Med. 10:e0009212023.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Mazari L, Ouarzane M and Zouali M:
Subversion of B lymphocyte tolerance by hydralazine, a potential
mechanism for drug-induced lupus. Proc Natl Acad Sci USA.
104:6317–6322. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Tanaka S, Ise W, Inoue T, Ito A, Ono C,
Shima Y, Sakakibara S, Nakayama M, Fujii K, Miura I, et al: Tet2
and Tet3 in B cells are required to repress CD86 and prevent
autoimmunity. Nat Immunol. 21:950–961. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Hung KH, Woo YH, Lin IY, Liu CH, Wang LC,
Chen HY, Chiang BL and Lin KI: The KDM4A/KDM4C/NF-κB and WDR5
epigenetic cascade regulates the activation of B cells. Nucleic
Acids Res. 46:5547–5560. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Rohraff DM, He Y, Farkash EA, Schonfeld M,
Tsou PS and Sawalha AH: Inhibition of EZH2 ameliorates lupus-like
disease in MRL/lpr mice. Arthritis Rheumatol. 71:1681–1690. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Gautam P, Sharma A and Bhatnagar A: Global
histone modification analysis reveals hypoacetylated H3 and H4
histones in B Cells from systemic lupus erythematosus patients.
Immunol Lett. 240:41–45. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Regna NL, Vieson MD, Gojmerac AM, Luo XM,
Caudell DL and Reilly CM: HDAC expression and activity is
upregulated in diseased lupus-prone mice. Int Immunopharmacol.
29:494–503. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Forster N, Gallinat S, Jablonska J, Weiss
S, Elsässer HP and Lutz W: p300 protein acetyltransferase activity
suppresses systemic lupus erythematosus-like autoimmune disease in
mice. J Immunol. 178:6941–6948. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Liu Y, Dong J, Mu R, Gao Y, Tan X, Li Y,
Li Z and Yang G: MicroRNA-30a promotes B cell hyperactivity in
patients with systemic lupus erythematosus by direct interaction
with Lyn. Arthritis Rheum. 65:1603–1611. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Luo S, Liu Y, Liang G, Zhao M, Wu H, Liang
Y, Qiu X, Tan Y, Dai Y, Yung S, et al: The role of microRNA-1246 in
the regulation of B cell activation and the pathogenesis of
systemic lupus erythematosus. Clin Epigenetics. 7:242015.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Wang M, Chen H, Qiu J, Yang HX, Zhang CY,
Fei YY, Zhao LD, Zhou JX, Wang L, Wu QJ, et al: Antagonizing miR-7
suppresses B cell hyperresponsiveness and inhibits lupus
development. J Autoimmun. 109:1024402020. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Garchow BG, Bartulos Encinas O, Leung YT,
Tsao PY, Eisenberg RA, Caricchio R, Obad S, Petri A, Kauppinen S
and Kiriakidou M: Silencing of microRNA-21 in vivo ameliorates
autoimmune splenomegaly in lupus mice. EMBO Mol Med. 3:605–615.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Yuan Y, Kasar S, Underbayev C,
Vollenweider D, Salerno E, Kotenko SV and Raveche E: Role of
microRNA-15a in autoantibody production in interferon-augmented
murine model of lupus. Mol Immunol. 52:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Xiao C, Srinivasan L, Calado DP, Patterson
HC, Zhang B, Wang J, Henderson JM, Kutok JL and Rajewsky K:
Lymphoproliferative disease and autoimmunity in mice with increased
miR-17-92 expression in lymphocytes. Nat Immunol. 9:405–414. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Jang S, Kwon EJ and Lee JJ: Rheumatoid
arthritis: Pathogenic roles of diverse immune cells. Int J Mol Sci.
23:9052022. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Smolen JS, Aletaha D and McInnes IB:
Rheumatoid arthritis. Lancet. 388:2023–2038. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Scott DL, Wolfe F and Huizinga TW:
Rheumatoid arthritis. Lancet. 376:1094–1108. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Julià A, Absher D, López-Lasanta M, Palau
N, Pluma A, Waite Jones L, Glossop JR, Farrell WE, Myers RM and
Marsal S: Epigenome-wide association study of rheumatoid arthritis
identifies differentially methylated loci in B cells. Hum Mol
Genet. 26:2803–2811. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
de Andres MC, Perez-Pampin E, Calaza M,
Santaclara FJ, Ortea I, Gomez-Reino JJ and Gonzalez A: Assessment
of global DNA methylation in peripheral blood cell subpopulations
of early rheumatoid arthritis before and after methotrexate.
Arthritis Res Ther. 17:2332015. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Ocskó T, Tóth DM, Hoffmann G, Tubak V,
Glant TT and Rauch TA: Transcription factor Zbtb38 downregulates
the expression of anti-inflammatory IL1r2 in mouse model of
rheumatoid arthritis. Biochim Biophys Acta Gene Regul Mech.
1861:1040–1047. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Tóth DM, Ocskó T, Balog A, Markovics A,
Mikecz K, Kovács L, Jolly M, Bukiej AA, Ruthberg AD, Vida A, et al:
Amelioration of autoimmune arthritis in mice treated with the DNA
methyltransferase inhibitor 5'-azacytidine. Arthritis Rheumatol.
71:1265–1275. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Li Y, Zhou M, Lv X, Song L, Zhang D, He Y,
Wang M, Zhao X, Yuan X, Shi G and Wang D: Reduced activity of HDAC3
and increased acetylation of histones H3 in peripheral blood
mononuclear cells of patients with rheumatoid arthritis. J Immunol
Res. 2018:73135152018. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Heinicke F, Zhong X, Flåm ST, Breidenbach
J, Leithaug M, Mæhlen MT, Lillegraven S, Aga AB, Norli ES,
Mjaavatten MD, et al: MicroRNA expression differences in
blood-derived CD19+ B cells of methotrexate treated rheumatoid
arthritis patients. Front Immunol. 12:6637362021. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Alivernini S, Kurowska-Stolarska M,
Tolusso B, Benvenuto R, Elmesmari A, Canestri S, Petricca L,
Mangoni A, Fedele AL, Di Mario C, et al: MicroRNA-155 influences
B-cell function through PU.1 in rheumatoid arthritis. Nat Commun.
7:129702016. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Kurowska-Stolarska M, Alivernini S,
Ballantine LE, Asquith DL, Millar NL, Gilchrist DS, Reilly J, Ierna
M, Fraser AR, Stolarski B, et al: MicroRNA-155 as a proinflammatory
regulator in clinical and experimental arthritis. Proc Natl Acad
Sci USA. 108:11193–11198. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Baldini C, Fulvio G, La Rocca G and Ferro
F: Update on the pathophysiology and treatment of primary Sjögren
syndrome. Nat Rev Rheumatol. 20:473–491. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Luppi F, Sebastiani M, Sverzellati N,
Cavazza A, Salvarani C and Manfredi A: Lung complications of
Sjogren syndrome. Eur Respir Rev. 29:2000212020. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Rischmueller M, Tieu J and Lester S:
Primary Sjogren's syndrome. Best Pract Res Clin Rheumatol.
30:189–220. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Miceli-Richard C, Wang-Renault SF,
Boudaoud S, Busato F, Lallemand C, Bethune K, Belkhir R, Nocturne
G, Mariette X and Tost J: Overlap between differentially methylated
DNA regions in blood B lymphocytes and genetic at-risk loci in
primary Sjögren's syndrome. Ann Rheum Dis. 75:933–940. 2016.
View Article : Google Scholar
|
|
130
|
Imgenberg-Kreuz J, Sandling JK, Almlöf JC,
Nordlund J, Signér L, Norheim KB, Omdal R, Rönnblom L, Eloranta ML,
Syvänen AC and Nordmark G: Genome-wide DNA methylation analysis in
multiple tissues in primary Sjögren's syndrome reveals regulatory
effects at interferon-induced genes. Ann Rheum Dis. 75:2029–2036.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Cole MB, Quach H, Quach D, Baker A, Taylor
KE, Barcellos LF and Criswell LA: Epigenetic signatures of salivary
gland inflammation in Sjogren's syndrome. Arthritis Rheumatol.
68:2936–2944. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Konsta OD, Le Dantec C, Charras A, Brooks
WH, Arleevskaya MI, Bordron A and Renaudineau Y: An in silico
approach reveals associations between genetic and epigenetic
factors within regulatory elements in B cells from primary
Sjögren's syndrome patients. Front Immunol. 6:4372015. View Article : Google Scholar
|
|
133
|
Inamo J, Suzuki K, Takeshita M, Kassai Y,
Takiguchi M, Kurisu R, Okuzono Y, Tasaki S, Yoshimura A and
Takeuchi T: Identification of novel genes associated with
dysregulation of B cells in patients with primary Sjögren's
syndrome. Arthritis Res Ther. 22:1532020. View Article : Google Scholar
|
|
134
|
Wang-Renault SF, Boudaoud S, Nocturne G,
Roche E, Sigrist N, Daviaud C, Bugge Tinggaard A, Renault V,
Deleuze JF, Mariette X and Tost J: Deregulation of microRNA
expression in purified T and B lymphocytes from patients with
primary Sjögren's syndrome. Ann Rheum Dis. 77:133–140. 2018.
View Article : Google Scholar
|
|
135
|
Daridon C, Devauchelle V, Hutin P, Le
Berre R, Martins-Carvalho C, Bendaoud B, Dueymes M, Saraux A,
Youinou P and Pers JO: Aberrant expression of BAFF by B lymphocytes
infiltrating the salivary glands of patients with primary Sjögren's
syndrome. Arthritis Rheum. 56:1134–1144. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Oh J, Vidal-Jordana A and Montalban X:
Multiple sclerosis: Clinical aspects. Curr Opin Neurol. 31:752–759.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Wang Y, Wang J and Feng J: Multiple
sclerosis and pregnancy: Pathogenesis, influencing factors, and
treatment options. Autoimmun Rev. 22:1034492023. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Comi G, Bar-Or A, Lassmann H, Uccelli A,
Hartung HP, Montalban X, Sørensen PS, Hohlfeld R and Hauser SL:
Expert Panel of the 27th Annual Meeting of the European Charcot
Foundation: Role of B cells in multiple sclerosis and related
disorders. Ann Neurol. 89:13–23. 2021. View Article : Google Scholar
|
|
139
|
Cencioni MT, Mattoscio M, Magliozzi R,
Bar-Or A and Muraro PA: B cells in multiple sclerosis-from targeted
depletion to immune reconstitution therapies. Nat Rev Neurol.
17:399–414. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Bar-Or A, Fawaz L, Fan B, Darlington PJ,
Rieger A, Ghorayeb C, Calabresi PA, Waubant E, Hauser SL, Zhang J
and Smith CH: Abnormal B-cell cytokine responses a trigger of
T-cell-mediated disease in MS? Ann Neurol. 67:452–461. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Li R, Rezk A, Miyazaki Y, Hilgenberg E,
Touil H, Shen P, Moore CS, Michel L, Althekair F, Rajasekharan S,
et al: Proinflammatory GM-CSF-producing B cells in multiple
sclerosis and B cell depletion therapy. Sci Transl Med.
7:310ra1662015. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Kappos L, Li D, Calabresi PA, O'Connor P,
Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J and
Hauser SL: Ocrelizumab in relapsing-remitting multiple sclerosis: A
phase 2, randomised, placebo-controlled, multicentre trial. Lancet.
378:1779–1787. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Ewing E, Kular L, Fernandes SJ,
Karathanasis N, Lagani V, Ruhrmann S, Tsamardinos I, Tegner J,
Piehl F, Gomez-Cabrero D and Jagodic M: Combining evidence from
four immune cell types identifies DNA methylation patterns that
implicate functionally distinct pathways during multiple sclerosis
progression. EBioMedicine. 43:411–423. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Maltby VE, Lea RA, Graves MC, Sanders KA,
Benton MC, Tajouri L, Scott RJ and Lechner-Scott J: Genome-wide DNA
methylation changes in CD19+ B cells from
relapsing-remitting multiple sclerosis patients. Sci Rep.
8:174182018. View Article : Google Scholar
|
|
145
|
Ma Q, Shams H, Didonna A, Baranzini SE,
Cree BAC, Hauser SL, Henry RG and Oksenberg JR: Integration of
epigenetic and genetic profiles identifies multiple sclerosis
disease-critical cell types and genes. Commun Biol. 6:3422023.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Annibali V, Umeton R, Palermo A, Severa M,
Etna MP, Giglio S, Romano S, Ferraldeschi M, Buscarinu MC,
Vecchione A, et al: Analysis of coding and non-coding transcriptome
of peripheral B cells reveals an altered interferon response factor
(IRF)-1 pathway in multiple sclerosis patients. J Neuroimmunol.
324:165–171. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Lindberg RLP, Hoffmann F, Mehling M, Kuhle
J and Kappos L: Altered expression of miR-17-5p in CD4+ lymphocytes
of relapsing-remitting multiple sclerosis patients. Eur J Immunol.
40:888–898. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Sievers C, Meira M, Hoffmann F, Fontoura
P, Kappos L and Lindberg RLP: Altered microRNA expression in B
lymphocytes in multiple sclerosis: Towards a better understanding
of treatment effects. Clin Immunol. 144:70–79. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Miyazaki Y, Li R, Rezk A, Misirliyan H,
Moore C, Farooqi N, Solis M, Goiry LG, de Faria O Junior, Dang VD,
et al: A novel microRNA-132-sirtuin-1 axis underlies aberrant
B-cell cytokine regulation in patients with relapsing-remitting
multiple sclerosis [corrected]. PLoS One. 9:e1054212014. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Syed FZ: Type 1 diabetes mellitus. Ann
Intern Med. 175:ITC33–ITC48. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Wang YN, Li R, Huang Y, Chen H, Nie H, Liu
L, Zou X, Zhong J, Zheng B and Gong Q: The role of B cells in the
pathogenesis of type 1 diabetes. Front Immunol. 15:14503662024.
View Article : Google Scholar
|
|
152
|
Stefan M, Zhang W, Concepcion E, Yi Z and
Tomer Y: DNA methylation profiles in type 1 diabetes twins point to
strong epigenetic effects on etiology. J Autoimmun. 50:33–37. 2014.
View Article : Google Scholar :
|
|
153
|
Paul DS, Teschendorff AE, Dang MAN, Lowe
R, Hawa MI, Ecker S, Beyan H, Cunningham S, Fouts AR, Ramelius A,
et al: Increased DNA methylation variability in type 1 diabetes
across three immune effector cell types. Nat Commun. 7:135552016.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Miao F, Smith DD, Zhang L, Min A, Feng W
and Natarajan R: Lymphocytes from patients with type 1 diabetes
display a distinct profile of chromatin histone H3 lysine 9
dimethylation: An epigenetic study in diabetes. Diabetes.
57:3189–3198. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Berry GJ, Budgeon LR, Cooper TK,
Christensen ND and Waldner H: The type 1 diabetes resistance locus
B10 Idd9.3 mediates impaired B-cell lymphopoiesis and implicates
microRNA-34a in diabetes protection. Eur J Immunol. 44:1716–1727.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Zou D, Feng S, Hu B, Guo M, Lv Y, Ma R, Du
Y and Feng J: Bromodomain proteins as potential therapeutic targets
for B-cell non-Hodgkin lymphoma. Cell Biosci. 14:1432024.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Martelli M, Ferreri AJM, Agostinelli C, Di
Rocco A, Pfreundschuh M and Pileri SA: Diffuse large B-cell
lymphoma. Crit Rev Oncol Hematol. 87:146–171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Melnik BC, Stadler R, Weiskirchen R,
Leitzmann C and Schmitz G: Potential pathogenic impact of Cow's
milk consumption and bovine milk-derived exosomal MicroRNAs in
diffuse large B-cell lymphoma. Int J Mol Sci. 24:61022023.
View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Morin RD, Mendez-Lago M, Mungall AJ, Goya
R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field
M, et al: Frequent mutation of histone-modifying genes in
non-Hodgkin lymphoma. Nature. 476:298–303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
You H, Xu-Monette ZY, Wei L, Nunns H, Nagy
ML, Bhagat G, Fang X, Zhu F, Visco C, Tzankov A, et al: Genomic
complexity is associated with epigenetic regulator mutations and
poor prognosis in diffuse large B-cell lymphoma. Oncoimmunology.
10:19283652021. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Ortega-Molina A, Boss IW, Canela A, Pan H,
Jiang Y, Zhao C, Jiang M, Hu D, Agirre X, Niesvizky I, et al: The
histone lysine methyltransferase KMT2D sustains a gene expression
program that represses B cell lymphoma development. Nat Med.
21:1199–1208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Pasqualucci L, Trifonov V, Fabbri G, Ma J,
Rossi D, Chiarenza A, Wells VA, Grunn A, Messina M, Elliot O, et
al: Analysis of the coding genome of diffuse large B-cell lymphoma.
Nat Genet. 43:830–837. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
163
|
Pasqualucci L, Dominguez-Sola D, Chiarenza
A, Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma
J, et al: Inactivating mutations of acetyltransferase genes in
B-cell lymphoma. Nature. 471:189–195. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Marquard L, Poulsen CB, Gjerdrum LM, de
Nully Brown P, Christensen IJ, Jensen PB, Sehested M, Johansen P
and Ralfkiaer E: Histone deacetylase 1, 2, 6 and acetylated histone
H4 in B- and T-cell lymphomas. Histopathology. 54:688–698. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Cosenza M and Pozzi S: The therapeutic
strategy of HDAC6 inhibitors in lymphoproliferative disease. Int J
Mol Sci. 19:23372018. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Kawaguchi Y, Kovacs JJ, McLaurin A, Vance
JM, Ito A and Yao TP: The deacetylase HDAC6 regulates aggresome
formation and cell viability in response to misfolded protein
stress. Cell. 115:727–738. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Kovacs JJ, Murphy PJM, Gaillard S, Zhao X,
Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB and Yao TP: HDAC6
regulates Hsp90 acetylation and chaperone-dependent activation of
glucocorticoid receptor. Mol Cell. 18:601–607. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Amara K, Ziadi S, Hachana M, Soltani N,
Korbi S and Trimeche M: DNA methyltransferase DNMT3b protein
overexpression as a prognostic factor in patients with diffuse
large B-cell lymphomas. Cancer Sci. 101:1722–1730. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Loo SK, Ab Hamid SS, Musa M and Wong KK:
DNMT1 is associated with cell cycle and DNA replication gene sets
in diffuse large B-cell lymphoma. Pathol Res Pract. 214:134–143.
2018. View Article : Google Scholar
|
|
170
|
Asmar F, Punj V, Christensen J, Pedersen
MT, Pedersen A, Nielsen AB, Hother C, Ralfkiaer U, Brown P,
Ralfkiaer E, et al: Genome-wide profiling identifies a DNA
methylation signature that associates with TET2 mutations in
diffuse large B-cell lymphoma. Haematologica. 98:1912–1920. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Mouly E, Ghamlouch H, Della-Valle V,
Scourzic L, Quivoron C, Roos-Weil D, Pawlikowska P, Saada V, Diop
MK, Lopez CK, et al: B-cell tumor development in Tet2-deficient
mice. Blood Adv. 2:703–714. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Dominguez PM, Ghamlouch H, Rosikiewicz W,
Kumar P, Béguelin W, Fontán L, Rivas MA, Pawlikowska P, Armand M,
Mouly E, et al: TET2 deficiency causes germinal center hyperplasia,
impairs plasma cell differentiation, and promotes B-cell
lymphomagenesis. Cancer Discov. 8:1632–1653. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap
YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H,
Lobry C, et al: TET1 is a tumor suppressor of hematopoietic
malignancy. Nat Immunol. 16:653–662. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Tian X, Pelton A, Shahsafaei A and Dorfman
DM: Differential expression of enhancer of zeste homolog 2 (EZH2)
protein in small cell and aggressive B-cell non-Hodgkin lymphomas
and differential regulation of EZH2 expression by p-ERK1/2 and MYC
in aggressive B-cell lymphomas. Mod Pathol. 29:1050–1057. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
175
|
McCabe MT, Ott HM, Ganji G, Korenchuk S,
Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A III,
Diaz E, et al: EZH2 inhibition as a therapeutic strategy for
lymphoma with EZH2-activating mutations. Nature. 492:108–112. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Caganova M, Carrisi C, Varano G, Mainoldi
F, Zanardi F, Germain PL, George L, Alberghini F, Ferrarini L,
Talukder AK, et al: Germinal center dysregulation by histone
methyltransferase EZH2 promotes lymphomagenesis. J Clin Invest.
123:5009–5022. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Cheng Y, Fu Y, Wang Y and Wang J: The m6A
methyltransferase METTL3 is functionally implicated in DLBCL
development by regulating m6A modification in PEDF. Front Genet.
11:9552020. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
He L, Thomson JM, Hemann MT,
Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe
SW, Hannon GJ and Hammond SM: A microRNA polycistron as a potential
human oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Tagawa H, Karube K, Tsuzuki S, Ohshima K
and Seto M: Synergistic action of the microRNA-17 polycistron and
Myc in aggressive cancer development. Cancer Sci. 98:1482–1490.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Roehle A, Hoefig KP, Repsilber D, Thorns
C, Ziepert M, Wesche KO, Thiere M, Loeffler M, Klapper W,
Pfreundschuh M, et al: MicroRNA signatures characterize diffuse
large B-cell lymphomas and follicular lymphomas. Br J Haematol.
142:732–744. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Lawrie CH, Chi J, Taylor S, Tramonti D,
Ballabio E, Palazzo S, Saunders NJ, Pezzella F, Boultwood J,
Wainscoat JS and Hatton CS: Expression of microRNAs in diffuse
large B cell lymphoma is associated with immunophenotype, survival
and transformation from follicular lymphoma. J Cell Mol Med.
13:1248–1260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Carbone A, Roulland S, Gloghini A, Younes
A, von Keudell G, López-Guillermo A and Fitzgibbon J: Follicular
lymphoma. Nat Rev Dis Primers. 5:832019. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Green MR: Chromatin modifying gene
mutations in follicular lymphoma. Blood. 131:595–604. 2018.
View Article : Google Scholar :
|
|
184
|
Green MR, Kihira S, Liu CL, Nair RV,
Salari R, Gentles AJ, Irish J, Stehr H, Vicente-Dueñas C,
Romero-Camarero I, et al: Mutations in early follicular lymphoma
progenitors are associated with suppressed antigen presentation.
Proc Natl Acad Sci USA. 112:E1116–E1125. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Morin RD, Johnson NA, Severson TM, Mungall
AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, et
al: Somatic mutations altering EZH2 (Tyr641) in follicular and
diffuse large B-cell lymphomas of germinal-center origin. Nat
Genet. 42:181–185. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
186
|
Béguelin W, Teater M, Meydan C, Hoehn KB,
Phillip JM, Soshnev AA, Venturutti L, Rivas MA, Calvo-Fernández MT,
Gutierrez J, et al: Mutant EZH2 induces a pre-malignant lymphoma
niche by reprogramming the immune response. Cancer Cell.
37:655–673.e11. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Zhang J, Vlasevska S, Wells VA, Nataraj S,
Holmes AB, Duval R, Meyer SN, Mo T, Basso K, Brindle PK, et al: The
CREBBP acetyltransferase is a haploinsufficient tumor suppressor in
B-cell lymphoma. Cancer Discov. 7:322–337. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Antoniolli M, Solovey M, Hildebrand JA,
Freyholdt T, Strobl CD, Bararia D, Keay WD, Adolph L, Heide M,
Passerini V, et al: ARID1A mutations protect follicular lymphoma
from FAS-dependent immune surveillance by reducing
RUNX3/ETS1-driven FAS-expression. Cell Death Differ. 32:899–910.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Wang W, Corrigan-Cummins M, Hudson J,
Maric I, Simakova O, Neelapu SS, Kwak LW, Janik JE, Gause B, Jaffe
ES and Calvo KR: MicroRNA profiling of follicular lymphoma
identifies microRNAs related to cell proliferation and tumor
response. Haematologica. 97:586–594. 2012. View Article : Google Scholar :
|
|
190
|
Ryan CE, Armand P and LaCasce AS:
Frontline management of mantle cell lymphoma. Blood. 145:663–672.
2025. View Article : Google Scholar
|
|
191
|
López C, Silkenstedt E, Dreyling M and Beà
S: Biological and clinical determinants shaping heterogeneity in
mantle cell lymphoma. Blood Adv. 8:3652–3664. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Hill HA, Qi X, Jain P, Nomie K, Wang Y,
Zhou S and Wang ML: Genetic mutations and features of mantle cell
lymphoma: A systematic review and meta-analysis. Blood Adv.
4:2927–2938. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Greiner TC, Dasgupta C, Ho VV,
Weisenburger DD, Smith LM, Lynch JC, Vose JM, Fu K, Armitage JO,
Braziel RM, et al: Mutation and genomic deletion status of ataxia
telangiectasia mutated (ATM) and p53 confer specific gene
expression profiles in mantle cell lymphoma. Proc Natl Acad Sci
USA. 103:2352–2357. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Kridel R, Meissner B, Rogic S, Boyle M,
Telenius A, Woolcock B, Gunawardana J, Jenkins CE, Cochrane C,
Ben-Neriah S, et al: Whole transcriptome sequencing reveals
recurrent NOTCH1 mutations in mantle cell lymphoma. Blood.
119:1963–1971. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Enjuanes A, Albero R, Clot G, Navarro A,
Beà S, Pinyol M, Martín-Subero JI, Klapper W, Staudt LM, Jaffe ES,
et al: Genome-wide methylation analyses identify a subset of mantle
cell lymphoma with a high number of methylated CpGs and aggressive
clinicopathological features. Int J Cancer. 133:2852–2863. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Li XY, Li Y, Zhang L, Liu X, Feng L and
Wang X: The antitumor effects of arsenic trioxide in mantle cell
lymphoma via targeting Wnt/β-catenin pathway and DNA
methyltransferase-1. Oncol Rep. 38:3114–3120. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Queirós Ana C, Beekman R, Vilarrasa-Blasi
R, Duran-Ferrer M, Clot G, Merkel A, Raineri E, Russiñol N,
Castellano G, Beà S, et al: Decoding the DNA methylome of mantle
cell lymphoma in the light of the entire B cell lineage. Cancer
Cell. 30:806–821. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Xargay-Torrent S, López-Guerra M,
Saborit-Villarroya I, Rosich L, Campo E, Roué G and Colomer D:
Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by
acetylation of proapoptotic BH3-only gene promoters. Clin Cancer
Res. 17:3956–3968. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
West AC and Johnstone RW: New and emerging
HDAC inhibitors for cancer treatment. J Clin Invest. 124:30–39.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Zhang J, Jima D, Moffitt AB, Liu Q, Czader
M, Hsi ED, Fedoriw Y, Dunphy CH, Richards KL, Gill JI, et al: The
genomic landscape of mantle cell lymphoma is related to the
epigenetically determined chromatin state of normal B cells. Blood.
123:2988–2996. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Zhang J, Dominguez-Sola D, Hussein S, Lee
JE, Holmes AB, Bansal M, Vlasevska S, Mo T, Tang H, Basso K, et al:
Disruption of KMT2D perturbs germinal center B cell development and
promotes lymphomagenesis. Nat Med. 21:1190–1198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Demosthenous C, Gupta SK, Sun J, Wang Y,
Troska TP and Gupta M: Deregulation of polycomb repressive
complex-2 in mantle cell lymphoma confers growth advantage by
epigenetic suppression of cdkn2b. Front Oncol. 10:12262020.
View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Zhao JJ, Lin J, Lwin T, Yang H, Guo J,
Kong W, Dessureault S, Moscinski LC, Rezania D, Dalton WS, et al:
microRNA expression profile and identification of miR-29 as a
prognostic marker and pathogenetic factor by targeting CDK6 in
mantle cell lymphoma. Blood. 115:2630–2639. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Di Lisio L, Gómez-López G, Sánchez-Beato
M, Gómez-Abad C, Rodríguez ME, Villuendas R, Ferreira BI, Carro A,
Rico D, Mollejo M, et al: Mantle cell lymphoma: Transcriptional
regulation by microRNAs. Leukemia. 24:1335–1342. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Robaina MC, Mazzoccoli L, Arruda VO, Reis
FR, Apa AG, de Rezende LM and Klumb CE: Deregulation of DNMT1,
DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution
for disease pathogenesis. Exp Mol Pathol. 98:200–207. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Dorsett Y, McBride KM, Jankovic M,
Gazumyan A, Thai TH, Robbiani DF, Di Virgilio M, Reina San-Martin
B, Heidkamp G, Schwickert TA, et al: MicroRNA-155 suppresses
activation-induced cytidine deaminase-mediated Myc-Igh
translocation. Immunity. 28:630–638. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Wang M, Yang W, Li M and Li Y: Low
expression of miR-150 in pediatric intestinal Burkitt lymphoma. Exp
Mol Pathol. 96:261–266. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Di Lisio L, Sánchez-Beato M, Gómez-López
G, Rodríguez ME, Montes-Moreno S, Mollejo M, Menárguez J, Martínez
MA, Alves FJ, Pisano DG, et al: MicroRNA signatures in B-cell
lymphomas. Blood Cancer J. 2:e572012. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Bueno MJ, Gómez de Cedrón M, Gómez-López
G, Pérez de Castro I, Di Lisio L, Montes-Moreno S, Martínez N,
Guerrero M, Sánchez-Martínez R, Santos J, et al: Combinatorial
effects of microRNAs to suppress the Myc oncogenic pathway. Blood.
117:6255–6266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Zucca E, Arcaini L, Buske C, Johnson PW,
Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K,
Thieblemont C, et al: Marginal zone lymphomas: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 31:17–29. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Dierlamm J, Baens M, Wlodarska I,
Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK, De Wolf-Peeters
C, Hagemeijer A, Van den Berghe H and Marynen P: The apoptosis
inhibitor gene API2 and a novel 18q gene, MLT, are recurrently
rearranged in the t(11;18)(q21;q21) associated with
mucosa-associated lymphoid tissue lymphomas. Blood. 93:3601–3609.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Willis TG, Jadayel DM, Du MQ, Peng H,
Perry AR, Abdul-Rauf M, Price H, Karran L, Majekodunmi O, Wlodarska
I, et al: Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell
lymphoma and mutated in multiple tumor types. Cell. 96:35–45. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Streubel B, Lamprecht A, Dierlamm J,
Cerroni L, Stolte M, Ott G, Raderer M and Chott A:
T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal
aberration in MALT lymphoma. Blood. 101:2335–2339. 2003. View Article : Google Scholar
|
|
214
|
Bühler MM, Martin-Subero JI,
Pan-Hammarström Q, Campo E and Rosenquist R: Towards precision
medicine in lymphoid malignancies. J Intern Med. 292:221–242. 2022.
View Article : Google Scholar
|
|
215
|
Mirandari A, Parker H, Ashton-Key M,
Stevens B, Walewska R, Stamatopoulos K, Bryant D, Oscier DG, Gibson
J and Strefford JC: The genomic and molecular landscape of splenic
marginal zone lymphoma, biological and clinical implications.
Explor Target Antitumor Ther. 5:877–901. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Arribas AJ, Rinaldi A, Mensah AA, Kwee I,
Cascione L, Robles EF, Martinez-Climent JA, Oscier D, Arcaini L,
Baldini L, et al: DNA methylation profiling identifies two splenic
marginal zone lymphoma subgroups with different clinical and
genetic features. Blood. 125:1922–1931. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Arribas AJ, Campos-Martín Y, Gómez-Abad C,
Algara P, Sánchez-Beato M, Rodriguez-Pinilla MS, Montes-Moreno S,
Martinez N, Alves-Ferreira J, Piris MA and Mollejo M: Nodal
marginal zone lymphoma: Gene expression and miRNA profiling
identify diagnostic markers and potential therapeutic targets.
Blood. 119:e9–e21. 2012. View Article : Google Scholar
|
|
218
|
Xiao F, Rui K, Shi X, Wu H, Cai X, Lui KO,
Lu Q, Ballestar E, Tian J, Zou H and Lu L: Epigenetic regulation of
B cells and its role in autoimmune pathogenesis. Cell Mol Immunol.
19:1215–1234. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Lanata CM, Paranjpe I, Nititham J, Taylor
KE, Gianfrancesco M, Paranjpe M, Andrews S, Chung SA, Rhead B,
Barcellos LF, et al: A phenotypic and genomics approach in a
multi-ethnic cohort to subtype systemic lupus erythematosus. Nat
Commun. 10:39022019. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Imgenberg-Kreuz J, Almlöf JC, Leonard D,
Sjöwall C, Syvänen AC, Rönnblom L, Sandling JK and Nordmark G:
Shared and unique patterns of DNA methylation in systemic lupus
erythematosus and primary Sjögren's syndrome. Front Immunol.
10:16862019. View Article : Google Scholar
|
|
221
|
Imgenberg-Kreuz J, Rasmussen A, Sivils K
and Nordmark G: Genetics and epigenetics in primary Sjögren's
syndrome. Rheumatology (Oxford). 60:2085–2098. 2021. View Article : Google Scholar
|
|
222
|
Zhang K, Luo Z, Yao X, Lu D, Hong T, Zhu
X, Chen M and Wang X: Identification of epigenetic alteration of
the IFI44L gene in B cells of sjogren's syndrome as a clinical
biomarker and molecular significance. J Inflamm Res. 18:2499–2512.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Nair N, Plant D, Verstappen SM, Isaacs JD,
Morgan AW, Hyrich KL, Barton A and Wilson AG; MATURA investigators:
Differential DNA methylation correlates with response to
methotrexate in rheumatoid arthritis. Rheumatology (Oxford).
59:1364–1371. 2020. View Article : Google Scholar
|
|
224
|
Kiselev IS, Kulakova OG, Boyko AN and
Favorova OO: DNA methylation as an epigenetic mechanism in the
development of multiple sclerosis. Acta Naturae. 13:45–57. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Wang F, Gao Y, Chen Y, Li P, Zeng Y, Chen
Y, Yin Y, Jia Y and Wang Y: Development of a mitochondria-related
gene signature for prognostic assessment in diffuse large B cell
lymphoma. Front Oncol. 15:15428292025. View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Xie Z, Li M, Hong H, Xu Q, He Z and Peng
Z: Expression of N6-methyladenosine (m6A)
regulators correlates with immune microenvironment characteristics
and predicts prognosis in diffuse large cell lymphoma (DLBCL).
Bioengineered. 12:6115–6133. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Rosikiewicz W, Chen X, Dominguez PM,
Ghamlouch H, Aoufouchi S, Bernard OA, Melnick A and Li S: TET2
deficiency reprograms the germinal center B cell epigenome and
silences genes linked to lymphomagenesis. Sci Adv. 6:eaay58722020.
View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Amin R and Braza MS: The follicular
lymphoma epigenome regulates its microenvironment. J Exp Clin
Cancer Res. 41:212022. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Straining R and Eighmy W: Tazemetostat:
EZH2 inhibitor. J Adv Pract Oncol. 13:158–163. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
230
|
Morschhauser F, Tilly H, Chaidos A, McKay
P, Phillips T, Assouline S, Batlevi CL, Campbell P, Ribrag V, Damaj
GL, et al: Tazemetostat for patients with relapsed or refractory
follicular lymphoma: An open-label, single-arm, multicentre, phase
2 trial. Lancet Oncol. 21:1433–1442. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Niccolai R, Göbel C, Ndoj K, Kreft M,
Kuiken HJ, Lieftink C, Morris B, Yska SD, Hendrix S, van den Broek
B, et al: Cholesterol biosynthesis as a drug-induced vulnerability
in diffuse large B cell lymphoma insensitive to EZH2 inhibition.
Neoplasia. 70:1012432025. View Article : Google Scholar : PubMed/NCBI
|
|
232
|
Heward J, Konali L, D'Avola A, Close K,
Yeomans A, Philpott M, Dunford J, Rahim T, Al Seraihi AF, Wang J,
et al: KDM5 inhibition offers a novel therapeutic strategy for the
treatment of KMT2D mutant lymphomas. Blood. 138:370–381. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
233
|
Jiang Y, Ortega-Molina A, Geng H, Ying HY,
Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre X, et al:
CREBBP inactivation promotes the development of HDAC3-dependent
lymphomas. Cancer Discov. 7:38–53. 2017. View Article : Google Scholar
|
|
234
|
Mondello P, Tadros S, Teater M, Fontan L,
Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, et al:
Selective inhibition of HDAC3 targets synthetic vulnerabilities and
activates immune surveillance in lymphoma. Cancer Discov.
10:440–459. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
235
|
Straus DJ, Hamlin PA, Matasar MJ, Lia
Palomba M, Drullinsky PR, Zelenetz AD, Gerecitano JF, Noy A,
Hamilton AM, Elstrom R, et al: Phase I/II trial of vorinostat with
rituximab, cyclophosphamide, etoposide and prednisone as palliative
treatment for elderly patients with relapsed or refractory diffuse
large B-cell lymphoma not eligible for autologous stem cell
transplantation. Br J Haematol. 168:663–670. 2015. View Article : Google Scholar
|
|
236
|
Jiang M, Huang F, Hong X, Xu C, Zhang B,
Hu S, Wang G, Hu D, Sun W, Lu Q, et al: PQQ inhibits PRC2
methyltransferase activity and suppresses the proliferation of
B-cell lymphoma in vitro. Chem Biodivers. 22:e2025001982025.
View Article : Google Scholar : PubMed/NCBI
|
|
237
|
Vijaykrishnaraj M, Patil P, Ghate SD,
Bhandary AK, Haridas VM and Shetty P: Efficacy of HDAC inhibitors
and epigenetic modulation in the amelioration of synovial
inflammation, cellular invasion, and bone erosion in rheumatoid
arthritis pathogenesis. Int Immunopharmacol. 122:1106442023.
View Article : Google Scholar : PubMed/NCBI
|
|
238
|
Regna NL, Vieson MD, Luo XM, Chafin CB,
Puthiyaveetil AG, Hammond SE, Caudell DL, Jarpe MB and Reilly CM:
Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in
NZB/W mice. Clin Immunol. 162:58–73. 2016. View Article : Google Scholar
|
|
239
|
Ren J, Catalina MD, Eden K, Liao X, Read
KA, Luo X, McMillan RP, Hulver MW, Jarpe M, Bachali P, et al:
Selective histone deacetylase 6 inhibition normalizes B cell
activation and germinal center formation in a model of systemic
lupus erythematosus. Front Immunol. 10:25122019. View Article : Google Scholar : PubMed/NCBI
|
|
240
|
Rosenthal AC, Munoz JL and Villasboas JC:
Clinical advances in epigenetic therapies for lymphoma. Clin
Epigenetics. 15:392023. View Article : Google Scholar : PubMed/NCBI
|
